# Study of BHV-3241 in Participants With Multiple System Atrophy

> **NCT03952806** · PHASE3 · COMPLETED · sponsor: **Biohaven Pharmaceuticals, Inc.** · enrollment: 421 (actual)

## Conditions studied

- Multiple System Atrophy

## Interventions

- **DRUG:** Verdiperstat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03952806
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-29
- **Primary completion:** 2021-07-29
- **Final completion:** 2022-06-30
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952806, "Study of BHV-3241 in Participants With Multiple System Atrophy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03952806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*